Sobi: EU committee backs Tryngolza in severe hypertriglyceridaemia; Ascendis Pharma: EU committee backs once-weekly Yuviwel in achondroplasia; Zealand Pharma: ZP9830 well tolerated in multiple-dose Phase 1.
Sobi, Ascendis Pharma, Zealand Pharma Beitrag lesen »
PolyPeptide: Samsung Biologics’ offer confirmed with 87.6% of shares tendered, but settlement slips to end-2026 or Q1 2027
Kuros Biosciences: 2026 guidance raised after 40% nine-month sales growth; Modus Therapeutics: sevuparin trial enrolment paused after a serious adverse event; Alvotech: first filing worldwide for a biosimilar of Eylea 8 mg; Heidelberg Pharma: nine-month figures, guidance and funding to mid-2027 confirmed; Lakefront Biotherapeutics: sells preclinical CAR-T programmes to Armed Cell Therapeutics.
Kuros, Heidelberg Pharma, Modus Therapeutics, Lakefront Biotherapeutics Beitrag lesen »
Lonza: higher profitability targets at its Capital Markets Day; BioNTech: BNT113 misses on progression-free survival, trial continues for overall survival; Evotec: nine-month figures above expectations, guidance confirmed; Zealand Pharma: AI protein deal with Generate Biomedicines; Oncopeptides: SEK 100M share issue for its glioblastoma programme.
Lonza, BioNTech, Evotec, Zealand Pharma, Oncopeptides Beitrag lesen »
PolyPeptide: Samsung Biologics’ takeover offer clears its acceptance threshold; Formycon: FDA accepts the filing for Keytruda biosimilar FYB206.
PolyPeptide, Formycon Beitrag lesen »
Idorsia: post hoc aprocitentan data at AHA Hypertension; Medincell: FDA approves Weltruza; Ascelia Pharma: Orviglance path after its FDA Type A meeting.
Idorsia, Medincell, Ascelia Pharma Beitrag lesen »
Also: GenSight’s GS030 optogenetics trial in NEJM and a €1.0M raise; Pharvaris’ RAPIDe-3 HAE data in The Lancet.
ADC Therapeutics raises $86.6M and resets its debt Beitrag lesen »
FDA keeps Newron hold, Zealand’s petrelintide Phase 2 win, Bavarian Nordic lifts guidance, UK pulls Valneva’s IXCHIQ.
Argenx halts efgartigimod Phase 3 in Sjögren’s Beitrag lesen »
Also: BridgeBio priority review, a rival to Ascendis; Lundbeck Parkinson’s data; Forbion’s €2.3bn funds; Alzinova rights issue.
Alvotech adds US capacity with LOTTE Biologics Beitrag lesen »
Also: Alvotech’s FDA capacity win, CSL–Alentis deal worth up to $1.6bn, new Idorsia data at AHA.
Genmab’s epcoritamab succeeds in frontline DLBCL Beitrag lesen »
